# Efficacy and Safety Evaluation of Sintilimab or Placebo in Combination With XELOX as First Line Treatment in Patients With Gastric Cancer

> **NCT03745170** · PHASE3 · COMPLETED · sponsor: **Innovent Biologics (Suzhou) Co. Ltd.** · enrollment: 650 (actual)

## Conditions studied

- Gastric Cancer

## Interventions

- **DRUG:** Sintilimab
- **DRUG:** Oxaliplatin
- **DRUG:** Capecitabine
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT03745170
- **Lead sponsor:** Innovent Biologics (Suzhou) Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-12-19
- **Primary completion:** 2021-06-20
- **Final completion:** 2022-10-21
- **Target enrollment:** 650 (ACTUAL)
- **Last updated:** 2023-03-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03745170

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03745170, "Efficacy and Safety Evaluation of Sintilimab or Placebo in Combination With XELOX as First Line Treatment in Patients With Gastric Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03745170. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*